Tab. Merison
Tablet · PO · 6mg / tablet · 1 tablet
৳2.01
Tab.
Merison
Betahistine Mesylate
— Square Pharmaceuticals Ltd.
6mg / tablet
Presentations
Dose rules
No structured dose rules are linked to this brand yet.
Dose reference
Human
Usually, for adults, administer orally 1 to 2 tablets three times per day after meals. The dose may be adjusted according to the age of patient and severity of symptoms.
Clinical notes
Applications:
N/A
Indication Notes:
Betahistine Mesylate is indicated in vertigo and dizziness associated with the following diseases: Meniere's disease, Meniere's syndrome, Peripheral vertigo.
Avoid In:
N/A
Contraindication Notes:
Hypersensitivity to betahistine mesylate, pheochromocytoma, peptic ulcer, acute bronchial asthma.
Betahistine Mesilate dilates precapillary sphincters, increasing the blood flow in the inner ear. It controls the permeability of capillaries in the inner ear, thereby removing endolymphatic hydrops. It also improves cerebral circulation, increasing blood flow in the internal carotid artery. Thus, Betahistine Mesylate is clinically useful for the relief of vertigo and dizziness.Betahistine Mesilate increases microcirculation blood flow in the inner ear, and removes endolymphatic hydrops of the inner ear. It also significantly increases the blood flow of the internal carotid artery. For discomfort accompanying cerebral disturbances: Betahistine exhibits a marked healing effect on giddiness experienced upon standing, the sensation of instability, and symptoms of dizziness. The heavy feeling in the head and the accompanying discomforts can also be successfully subdued. For dizziness and the sensation of dizziness due to disturbances in the inner ear: Betahistine improves microcirculation of the inner ear and removes endolymph hydrops, thereby alleviating dizziness in Meniere's disease and Meniere's syndrome. Tinnitus, the sensation of ear obstructions, nausea and vomiting are also effectively allayed. For the prevention of dizzy spells and other residual symptoms: Along with inhibiting the symptoms of dizziness and removing residual symptoms after the attack, continued administration of Betahistine Mesylate also prevents the recurrence of dizzy spells. As the primary in prescribing for dizziness: By the combined use with antihypertensive agents, therapeutic agents for arteriosclerosis, vitamins and tranquilizers, accompanying symptoms can also be brought into remission and better therapeutic effects obtained.
Digestive: Nausea or vomiting may rarely occur. Hypersensitivity: Hypersensitivity reactions, such as skin rash, may rarely occur.
Safety of Betahistine during pregnancy has not been established. This drug should be administered to pregnant patients or women suspected of being pregnant, only if the expected therapeutic benefit is thought to outweigh any possible risk.
Patients with a history of digestive ulcer or an active digestive ulcer, Patients with bronchial asthma, Patients with pheochromocytoma.